BioXcel Therapeutics Inc (FRA:BX2)
€ 1.892 0.006 (0.32%) Market Cap: 72.49 Mil Enterprise Value: 98.09 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 21/100

BioXcel Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 13, 2022 / 02:45PM GMT
Release Date Price: €16.95 (-4.78%)
Tessa Thomas Romero
JPMorgan Chase & Co, Research Division - Associate

Welcome, everyone, to the 40th Annual JPMorgan Healthcare conference. My name is Tessa Romero. I'm one of the senior biotechnology analyst here at JPMorgan. I'm joined by [Taylor Hanley] from the team. Our next presenting company is BioXcel Therapeutics. And presenting on behalf of the company, we have CEO, Vimal Mehta. Before I hand it over, I'd like to just remind all of our listeners to please use the "Ask a question" button in the portal to ask any of your question, and I'm happy to get it in on your behalf.

With that, I will hand it over to you.

Vimal D. Mehta
BioXcel Therapeutics, Inc. - Founder, CEO, President, & Director

Thank you, Tessa. Thank you to our host JPMorgan for the opportunity to present today. And good morning, all. We were eager to meet with you in person this year, but the unfortunate realities of the pandemic continue to force us into this virtual format. With that said, let's jump in and discuss the many exciting things that are happening at

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot